一种适用于静脉注射的新型改良免疫血清球蛋白（人）制剂。II. 功能特性

A new preparation of modified immune serum globulin (human) suitable for intravenous administration. II. Functional characterization.

作者信息

Schroeder D D, Tankersley D L, Lundblad J L

出版信息

Vox Sang. 1981;40(6):383-94. doi: 10.1111/j.1423-0410.1981.tb00726.x.

DOI:10.1111/j.1423-0410.1981.tb00726.x

Abstract

The commercial immune serum globulin (ISG) product is suitable for use in passive immunization only by intramuscular administration; intravenous use results in vasomotor side reactions. We report the functional characterization of a chemically modified ISG (MISG) that is essentially free of nonspecific complement-binding activity and contains no new antigenic determinants. The half-life values for MISG given intravenously to rabbits, guinea pigs, and humans are shown not to be different from that of ISG. The MISG we describe is shown to fulfill the in vitro and in vivo criteria of stability, safety, function, and half-life, making it suitable for human intravenous administration.

摘要

市售免疫血清球蛋白（ISG）产品仅适用于通过肌肉注射进行被动免疫；静脉使用会导致血管舒缩副作用。我们报告了一种化学修饰的ISG（MISG）的功能特性，该产品基本没有非特异性补体结合活性，且不含有新的抗原决定簇。静脉注射给兔子、豚鼠和人类的MISG半衰期值与ISG的半衰期值并无差异。我们所描述的MISG已证明符合稳定性、安全性、功能和半衰期的体外和体内标准，使其适合于人体静脉给药。